
AbCellera Biologics ABCL
$ 9.63
-7.85%
AbCellera Biologics ROE Ratio | ABCL
Annual ROE Ratio AbCellera Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15.14 | -15.42 | -12.7 | 12.85 | 14.96 | 14.32 | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.96 | -15.42 | -0.19 |
Quarterly ROE Ratio AbCellera Biologics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20.55 | -20.16 | -18.43 | -13.83 | -18.57 | -15.97 | -16.12 | -11.66 | -14.08 | -11.89 | -11.89 | -8.29 | -6.16 | -4.3 | 12.21 | 15.53 | 13.29 | 10.92 | 23.73 | 9.76 | 9.44 | 12.49 | 12.48 | 0.23 | -0.32 | 0.81 | -0.25 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23.73 | -20.55 | -2.65 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Chiasma, Inc.
CHMA
|
-81.47 | - | -6.00 % | $ 238 M | ||
|
vTv Therapeutics
VTVT
|
-41.86 | $ 16.0 | -2.2 % | $ 64.2 M | ||
|
Adamas Pharmaceuticals, Inc.
ADMS
|
114.86 | - | - | $ 376 M | ||
|
Cellect Biotechnology Ltd.
APOP
|
113.28 | - | 0.38 % | $ 12.9 M | ||
|
Xenon Pharmaceuticals
XENE
|
-59.46 | $ 36.89 | -1.78 % | $ 2.92 B | ||
|
Xeris Pharmaceuticals
XERS
|
4.05 | $ 16.95 | 2.02 % | $ 2.72 B | ||
|
AzurRx BioPharma, Inc.
AZRX
|
1237230757.23 | - | 2.07 % | $ 34.4 M | ||
|
X4 Pharmaceuticals
XFOR
|
-42.51 | $ 3.01 | 1.69 % | $ 127 M | ||
|
Cerecor Inc.
CERC
|
-258.53 | - | -1.68 % | $ 283 M | ||
|
Constellation Pharmaceuticals, Inc.
CNST
|
-30.76 | - | - | $ 1.63 B | ||
|
Auris Medical Holding Ltd.
EARS
|
-48.9 | - | -1.77 % | $ 39.2 M | ||
|
Dicerna Pharmaceuticals, Inc.
DRNA
|
-81.85 | - | 0.34 % | $ 2.98 B | ||
|
ERYTECH Pharma S.A.
ERYP
|
-0.97 | - | 1.3 % | $ 27.7 M | ||
|
GW Pharmaceuticals plc
GWPH
|
-7.84 | - | - | $ 6.81 B | ||
|
22nd Century Group
XXII
|
-32.07 | $ 0.32 | -19.83 % | $ 58.9 K | ||
|
Kadmon Holdings, Inc.
KDMN
|
-93.87 | - | - | $ 1.7 B | ||
|
Liminal BioSciences
LMNL
|
1.72 | - | - | $ 256 M | ||
|
argenx SE
ARGX
|
17.64 | $ 926.42 | -1.66 % | $ 56.8 B | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-50.59 | $ 2.33 | -7.25 % | $ 19.8 M | ||
|
Zai Lab Limited
ZLAB
|
-24.53 | $ 21.01 | -4.16 % | $ 23 B | ||
|
Neos Therapeutics, Inc.
NEOS
|
275.73 | - | -2.54 % | $ 57.2 M | ||
|
Zentalis Pharmaceuticals
ZNTL
|
-63.39 | $ 1.37 | 0.74 % | $ 98.5 M | ||
|
Zoetis
ZTS
|
80.25 | $ 78.81 | -2.47 % | $ 34.9 B | ||
|
Odonate Therapeutics, Inc.
ODT
|
-92.81 | - | -3.18 % | $ 58.5 M | ||
|
Orphazyme A/S
ORPH
|
-102.05 | - | -2.25 % | $ 31.3 M | ||
|
Osmotica Pharmaceuticals plc
OSMT
|
-84.8 | - | -10.74 % | $ 89.9 M | ||
|
Pandion Therapeutics, Inc.
PAND
|
-17745.54 | - | - | $ 1.77 B | ||
|
Xenetic Biosciences
XBIO
|
-36.25 | $ 1.47 | -4.55 % | $ 2.5 M | ||
|
Translate Bio, Inc.
TBIO
|
-15.08 | - | - | $ 2.81 B | ||
|
Trillium Therapeutics Inc.
TRIL
|
-21.28 | - | - | $ 1.94 B | ||
|
Urovant Sciences Ltd.
UROV
|
252.98 | - | - | $ 532 M | ||
|
Acceleron Pharma Inc.
XLRN
|
-14.6 | - | - | $ 10.9 B | ||
|
Zogenix, Inc.
ZGNX
|
-56.64 | - | -4.97 % | $ 664 M | ||
|
Yunhong International
ZGYH
|
-1.19 | - | 0.10 % | $ 92.2 M | ||
|
ZIOPHARM Oncology, Inc.
ZIOP
|
-64.51 | - | -7.58 % | $ 264 M | ||
|
Taysha Gene Therapies
TSHA
|
-44.14 | $ 3.71 | -1.72 % | $ 1.19 B | ||
|
Vericel Corporation
VCEL
|
4.66 | $ 57.41 | -1.46 % | $ 2.89 B | ||
|
Vir Biotechnology
VIR
|
-57.23 | $ 8.37 | -5.64 % | $ 1.16 B | ||
|
Veracyte
VCYT
|
5.07 | $ 25.08 | 0.16 % | $ 1.97 B | ||
|
Viking Therapeutics
VKTX
|
-56.28 | $ 24.72 | -4.35 % | $ 2.79 B | ||
|
Vanda Pharmaceuticals
VNDA
|
-67.39 | $ 3.44 | -6.27 % | $ 203 M | ||
|
VistaGen Therapeutics
VTGN
|
-196.2 | $ 0.16 | -12.33 % | $ 6.09 M | ||
|
Voyager Therapeutics
VYGR
|
-61.06 | $ 1.52 | -5.9 % | $ 89.2 M | ||
|
Verrica Pharmaceuticals
VRCA
|
-72.34 | $ 2.74 | -5.03 % | $ 29.2 M | ||
|
Wave Life Sciences Ltd.
WVE
|
-39.43 | $ 2.56 | -6.07 % | $ 432 M | ||
|
XBiotech
XBIT
|
-32.45 | $ 1.75 | 4.17 % | $ 53.4 M | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
-18.9 | $ 1.37 | -7.43 % | $ 922 M | ||
|
Adial Pharmaceuticals
ADIL
|
-151.18 | $ 3.15 | -35.42 % | $ 2.11 M | ||
|
ADMA Biologics
ADMA
|
30.78 | $ 13.18 | -1.2 % | $ 3.14 B | ||
|
Exicure
XCUR
|
-125.98 | $ 0.96 | -7.24 % | $ 6.05 M |